2025
Clinical Implications of Breast Cancer Intrinsic Subtypes
Rios-Hoyo A, Shan N, Karn P, Pusztai L. Clinical Implications of Breast Cancer Intrinsic Subtypes. Advances In Experimental Medicine And Biology 2025, 1464: 435-448. PMID: 39821037, DOI: 10.1007/978-3-031-70875-6_21.Peer-Reviewed Original ResearchConceptsBasal-like cancersBreast cancerDistant recurrenceLuminal cancersEndocrine therapyAdjuvant chemotherapyClinical behaviorOncotype DX recurrence scorePathologic complete response rateTreated with preoperative chemotherapyExcellent long-term survivalRisk of early recurrenceBasal-like breast cancerBreast cancer intrinsic subtypesHER2-enriched cancersImmunotherapy to chemotherapyLuminal A cancersComplete response rateImmune checkpoint inhibitorsEstrogen receptor-negativeHER2-targeted therapyEstrogen receptor-positiveLevel of immune infiltrationHER2 gene amplificationAdjuvant endocrine therapy
2013
Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer.
Natowicz R, Jiang T, Shi W, Qi Y, Delpech Y, Symmans W, Pusztai L. Correlation of intratumor gene expression heterogeneity with chemotherapy sensitivity in breast cancer. Journal Of Clinical Oncology 2013, 31: 1013-1013. DOI: 10.1200/jco.2013.31.15_suppl.1013.Peer-Reviewed Original ResearchPathologic complete responseBasal-like cancersBreast cancerNeoadjuvant chemotherapyChemotherapy sensitivityCancer subtypesLuminal B cancersDifferent molecular subtypesBreast cancer subtypesB cancersComplete responseLuminal cancersResidual diseaseMolecular subtypesStage ICancerGene signatureGreat heterogeneitySubtypesTumor heterogeneityChemotherapySignificant differences